CD22 and acute lymphoblastic leukemia: In our laboratory, for B-ALL lineage assignment, we used a comprehensive panel that included, in addition to CD79a, CD19, CD10, and CD22 recommended by the WHO, a cytoplasmatic and surface IgM.